Key Takeaways Incyte shares sank Monday after the drugmaker released the latest data from a clinical trial.The drug, ...
While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring data ...
Leading pharmaceutical companies, including Dr Reddy's, Sun Pharma, Cipla, Mankind Pharma, and Natco Pharma, among others, ...
Another company involved in using AI to repurpose failed drugs – as well as drugs that have already been approved – is ...
Tv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial ...
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to ...
An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in ...
AbbVie has reported analysis from a Phase III trial that assessed Elahere against chemotherapy for platinum-resistant ovarian ...
The study looked at patients with leukaemia, which occurs in bone marrow, and lymphoma, which affects the lymphatic system.
Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...
Cadisegliatin, which was paused in the third phase of its CATT1 trial, is taken orally and is designed to target the liver specifically and aims to treat diabetes by improving blood sugar control. VTv ...
Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have acquired NeuroRx, a leader in imaging analysis with expertise in multiple sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results